Randomized, double-blind trial shows diacylglycerol reduced low-density lipoprotein cholesterol in obese adults, indicating potential metabolic benefits.
Diacylglycerol (DAG) administration reduced small dense low-density lipoprotein cholesterol and hepatic steatosis and induced the enrichment of serum triacylglycerol and phosphatidylethanolamine species containing mono/polyunsaturated fatty acids.
No takes yet. Share an insight, caveat, or question.
Qin et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: